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Abstract
Background: Inflammation followed by fibrosis is a component of islet dysfunction in both rodent and human type 2
diabetes. Because islet inflammation may originate from endothelial cells, we assessed the expression of selected genes
involved in endothelial cell activation in islets from a spontaneous model of type 2 diabetes, the Goto-Kakizaki (GK) rat. We
also examined islet endotheliuml/oxidative stress (OS)/inflammation-related gene expression, islet vascularization and
fibrosis after treatment with the interleukin-1 (IL-1) receptor antagonist (IL-1Ra).
Methodology/Principal Findings: Gene expression was analyzed by quantitative RT-PCR on islets isolated from 10-week-old
diabetic GK and control Wistar rats. Furthermore, GK rats were treated s.c twice daily with IL-1Ra (Kineret, Amgen, 100 mg/
kg/day) or saline, from 4 weeks of age onwards (onset of diabetes). Four weeks later, islet gene analysis and pancreas
immunochemistry were performed. Thirty-two genes were selected encoding molecules involved in endothelial cell
activation, particularly fibrinolysis, vascular tone, OS, angiogenesis and also inflammation. All genes except those encoding
angiotensinogen and epoxide hydrolase (that were decreased), and 12-lipoxygenase and vascular endothelial growth factor
(that showed no change), were significantly up-regulated in GK islets. After IL-1Ra treatment of GK rats in vivo, most selected
genes implied in endothelium/OS/immune cells/fibrosis were significantly down-regulated. IL-1Ra also improved islet
vascularization, reduced fibrosis and ameliorated glycemia.
Conclusions/Significance: GK rat islets have increased mRNA expression of markers of early islet endothelial cell activation,
possibly triggered by several metabolic factors, and also some defense mechanisms. The beneficial effect of IL-1Ra on most
islet endothelial/OS/immune cells/fibrosis parameters analyzed highlights a major endothelial-related role for IL-1 in GK islet
alterations. Thus, metabolically-altered islet endothelium might affect the b-cell microenvironment and contribute to
progressive type 2 diabetic b-cell dysfunction in GK rats. Counteracting islet endothelial cell inflammation might be one way
to ameliorate/prevent b-cell dysfunction in type 2 diabetes.
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Introduction
The endothelium plays an important role in the regulation of
hemostasis, blood flow, maintenance of vascular architecture and
mononuclear cell migration, all of primary significance in
atherogenesis. The diabetic state is well known to be associated
with macrovascular complications such as atherosclerosis and
medial calcifications that lead to increased risk of cardiovascular
disease [1]. In addition, a diabetic-specific microvascular disease is
at work in the retina (retinopathy), kidney (glomerulopathy) and
vasa nervorum (neuropathy) [2].
Until now, the pancreatic islets have been only rarely
considered as being a possible ‘‘end-organ’’ of type 2 diabetes
(T2D). However, the islet has been shown to undergo significant
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e6963remodelling concurrently or even earlier than other end-organs
in T2D [3,4]. Indeed, some studies have demonstrated the
presence of fibrosis in various spontaneous T2D animal models,
and also the presence of amyloid deposits in type 2 diabetic
patients [3,5–7]. Moreover, we showed recently that inflam-
mation is present in the islets of type 2 diabetic animal models
and in humans [6,8,9]. In the spontaneously diabetic Goto-
Kakizaki (GK) rat, we suggested that these islet alterations were
reminiscent of microangiopathy [6,7]. Others, using electron
microscopy, have described signs of microangiopathy in young
but normoglycemic Zucker fatty rats and in the db/db mouse
[10,11].
Hyperglycemia and some other associated metabolic derange-
ments (increased free fatty acids (FFA) and/or insulin resistance),
which may precede hyperglycemia, mediate abnormal endothelial
cell (EC) function via increased oxidative stress (OS), disturbances
of intracellular signal transduction (such as protein kinase C
activation) and activation of receptors for advanced glycation end-
products (RAGE) [1–3,12–14]. These molecular events lead to: 1)
decreased nitric oxide (NO) availability associated with increased
levels of endothelin-1 (ET-1) and angiotensin II (A-II) with
resulting vasoconstriction and its consequences on blood flow and
vascular smooth muscle cell (VSMC) growth; 2) activation of
transcription factors such as nuclear factor kappa B (NF-kB) and
activator protein-1 (AP-1), which increases the expression of
cellular adhesion molecules such as intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1). It also stimulates the production of cytokines, for
example, IL-1 and chemokines, such as monocyte/macrophage
chemoattractant protein (MCP-1), leading to local inflammation,
leukocyte attraction/migration and reactive oxygen species (ROS)
production; 3) increased production of prothrombotic/dysfibrino-
lytic factors, such as tissue factor and plasminogen activator
inhibitor-1 (PAI-1), which induce hypercoagulation and platelet
aggregation [1,15].
Overall vascular function is dependent upon the balance of
pro-/antioxidant mechanisms, which determines endothelial
function [14]. Considerable evidence demonstrates that OS plays
a central role in the pathology of diabetes [16–18]. Among other
factors including obesity and insulin resistance, hyperglycemia
alone is able to directly induce OS [19–21]. Diabetes starts at
around 4 weeks of age (weaning) in GK rats. After 3 months of
mild hyperglycemia, GK islets show an upregulation of the gene
encoding thioredoxin-interacting protein [6], which is induced by
hyperglycemia and inhibits thioredoxin antioxidant function [22].
Also, ROS are involved in the mechanism of action of pro-
inflammatory cytokines, such as IL-1b and tumor necrosis factor-a
(TNF-a), known to be produced by EC and to target them [23–
28]. Therefore, based on the data presented above, we
hypothesized that T2D islet inflammation might have originated
from EC activation.
Here, we assessed in 10-week-old diabetic GK rats and Wistar
controls: 1) different circulating parameters linked to EC
dysfunction, OS, inflammation, and atherosclerosis; 2) the
expression of selected genes known to be involved in EC activation
in freshly isolated islets; 3) the effect of 1-month treatment with IL-
1Ra on islet expression of genes linked to endothelium, OS and
extracellular matrix proteins, and islet vascularization and fibrosis.
IL-1Ra has already been used in T2D and atherosclerosis [29–31].
Our data showed that endothelial activation is present in islets
from 10-week-old diabetic GK rats, concomitantly with inflam-
mation/OS. Moreover, IL-1Ra in vivo dampened these events,
ameliorating islet vascularization, reducing fibrosis and improving
glycemia.
Results
Dyslipidemia and signs of systemic OS in diabetic GK rats
Metabolic parameters for 10-week-old male control Wistar and
diabetic GK rats are summarized in Table 1. The body weight of
diabetic animals was significantly lower than controls. They
displayed mildly but significantly elevated fed blood glucose and
insulin levels [32]. They also showed hyperleptinemia and
significantly increased circulating levels of triglycerides, FFA, total
cholesterol and high density lipoproteins (HDL) cholesterol. Their
total cholesterol/HDL cholesterol ratio was similar to that of
Wistar rats. The glutathione redox state was significantly lower in
GK than Wistar red blood cells (RBC), with comparable
equivalent reduced glutathione contents (Eq GSH). Plasma a-
tocopherol level was significantly higher in GK animals than
controls. Concomitantly, the plasma homocysteine level, an
independent risk factor in the development of atherosclerosis
[33,34], was significantly lower. Moreover, the activity of
paraoxonase-1 (PON-1), an HDL-associated lipo-lactamase,
whose activity is negatively correlated with homocysteine [35],
was signicantly higher in diabetic than control animals. However,
circulating cytokines/chemokines levels, such as GRO1/KC (or
CXCL1, the rodent equivalent of IL-8), MCP-1 (CCL2), MIP-1a
(macrophage inflammatory protein-1a or CCL3) and IL-6 were
not significantly different at this age between both groups.
Table 1. Metabolic data for 10-week-old control Wistar and
diabetic GK male rats.
Parameters Wistar GK
Body weight (g) 384610 27768
*
Glucose (mM) 5.960.3 8.360.4
*
Insulin (pM) 184643 4406115
*
Leptin (pM) 250633 360617
*
Triglycerides (mM) 1.560.1 2.160.1
*
FFA (mM) 0.560.0 0.760.0
*
Total cholesterol (mM) 1.660.1 2.060.0
*
HDL cholesterol (mM) 1.160.1 1.460.0
*
Cholesterol/HDL ratio 1.460.0 1.460.0
RBC glutathione redox state 93.561.0 80.163.1
*
RBC Eq GSH content (mM) 3.960.3 3.860.3
a-Tocopherol (mM) 13.560.6 22.061.1
*
Homocysteine (mM) 9.960.6 6.060.3
*
PON-1 (%) 10064 11663
*
GRO1/KC (pg/ml) 312670 337637
MCP-1 (pg/ml) 153616 219645
MIP-1a (pg/ml) 6.460.8 7.662.5
IL-6 (pg/ml) 79621 2246113
Glucose, insulin, leptin, lipids, cytokine and chemokine levels were determined
in serum. Alpha-tocopherol and homocysteine levels, and paraoxonase-1 (PON-
1) activity were determined in plasma. Glutathione redox state (% of reduced
glutathione (GSH)) and GSH content (Eq GSH) were determined in red blood
cells (RBC). Glucose, insulin, leptin: n=7 per group; lipids: n=9 per group;
cytokines/chemokines: n=7 per group; a-tocopherol, glutathione redox state
and GSH content (n=7–13 per group) and homocysteine and PON-1: n=7–8
per group. All parameters were assayed under fed conditions. FFA (free fatty
acids); HDL: high density lipoproteins; GRO1/KC/CXCL1: rodent equivalent of IL-
8; MCP-1/CCL2: monocyte/macrophage chemoattractant protein; MIP-1a/CCL3:
macrophage inflammatory protein-1a; IL-6, interleukin-6.
*p,0.05 versus age-
matched Wistar group, as analyzed by Student’s t-test.
doi:10.1371/journal.pone.0006963.t001
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adult GK rats also exhibited hyperlipidemia, blood OS (as
reflected by oxidized RBC glutathione redox state), but had
already mounted blood antioxidant defense (high a-tocopherol
level and PON-1 activity).
Islet endothelial activation in diabetic GK rats
Hyperglycemia is well recognized to be associated with
increased arterial wall inflammation, reflected by increased
expression of anti-fibrinolytic components, vascular cell adhesion
molecules, renin-angiotensin system (RAS) factors, agents involved
in OS, vascular tone and angiogenesis, and also of cytokines,
chemokines, Toll-like receptors (TLRs) and molecules involved in
their signalling [1,15,25,28,36–38]. Therefore, we selected 32
genes encoding molecules belonging to these different classes.
Expression of these genes is shown in Table 2. Twenty-eight of 32
of the selected genes were significantly over-expressed. These
genes encoded the following molecules: 1) anti-fibrinolysis system:
PAI-1; 2) vascular adhesion molecules: E-selectin (E-SELE),
ICAM-1, platelet-endothelial cell-adhesion molecule-1 (PECAM-
1) and VECAM-1; 3) RAS: angiotensin-converting enzyme-1
(ACE-1) and angiotensin receptor-1a (AGTR-1a); 4) vascular
tone/OS/angiogenesis components: cyclo-oxygenase-2 (COX-2),
endothelial nitric oxide synthase (eNOS), endothelin-1 (ET-1),
heme-oxygenase-1 (HO-1), hypoxia-induced factor-1a (HIF-1a),
NADPH-oxidase-2 (NOX-2), prostacyclin synthase; 5) cytokines
and growth factors: IL-1b, IL-1Ra, IL-6, transforming growth
factor-b (TGF-b), tumor necrosis factor-a (TNF-a); 6) chemokines:
GRO1/KC, MCP-1, and MIP-1a; 7) cellular pathways for
cytokines and TLRs: caspase-1, TLR-2, TLR-4, myeloid differ-
entiation primary response protein MyD88, NF-kB and inductible
nitric oxide synthase (iNOS). The expression of 2 genes of 32 was
found to be significantly decreased, one encoding a molecule
belonging to RAS: angiotensinogen and the other encoding
soluble (cytoplasmic) epoxide hydrolase (sEH), involved in vascular
tone, OS, inflammation and angiogenesis. Finally, the gene
expression for the pro-oxidant 12-lipoxygenase (12-LOX) and
the pro-angiogenic factor vascular endothelial growth factor
(VEGF) was not modified. Thus, islets from 10-week-old diabetic
GK rats are characterized by increased mRNA levels of molecules
involved in dysfibrinolysis, endothelium cell adhesion, vascular
tone, OS and inflammation.
Beneficial effect of IL-1Ra on glycemia and expression of
genes selected for endothelial activation, OS and ECM,
and on vascularization and fibrosis in GK islets
Endothelial activation, OS and mechanisms of cytokine action
are tightly linked [23–28]. IL-1b, produced by EC among other
cells, is involved in microangiopathy/atherogenesis [28,39,40].
Therefore, we administered IL-1Ra, its natural antagonist, s.c.
twice daily at 50 mg/kg (i.e. 100 mg/kg/day) to GK rats, from 4
weeks (weaning and onset of diabetes) to 8 weeks of age. At the end
of treatment, IL-1Ra-treated GK rats showed a significantly lower
glycemia than GK saline (controls): 8.860.3 mM (n=7) and
7.960.1 mM (n=8, p,0.05), respectively.
GK rat IL-1Ra treatment down-regulated 80% of selected
genes. As shown in Fig. 1A, IL-1Ra treatment significantly (except
otherwise stated) decreased GK islet expression of genes encoding:
PAI-1 (261%), VCAM-1 (268%, ns), ACE-1 (274%), ET-1
(Edn1, 254%), NOX-2 (267%), COX-2 (260%), iNOS (254%),
prostacyclin synthase (Ptgis, 248%), and eNOS (255%) vs Wistar
controls. However, IL-1Ra treatment did not significantly reduce
islet endothelial gene expression for E-selectin (Sele) and HIF-1a.
The effects of IL-1Ra treatment on genes encoding antioxidant
molecules are shown in Fig. 1B. Beta-cells appear to be especially
vulnerable to ROS attacks due to their low levels of antioxidant
enzymes [41,42]. To compensate for such vulnerability, diabetic b
cells may upregulate antioxidant genes in vivo [43], as we recently
showed in GK islets [44]. Here, IL-1Ra treatment of GK rats was
able to down-regulate the expression of some of these genes but not
all of them. First, the gene expression of one of the main stress-
activated mitochondrial enzymes, superoxide dismutase 2 was
decreased (Sod2, 263%). This enzyme represents the first-line of
defense against superoxide anions generated by the mitochondria.
However, IL-1Ra did not modify the expression of Sod1 gene. IL-
1Ra further reduced significantly catalase (Cat, 234%), but not
glutathione peroxidase 1 (Gpx1), nor thioredoxin 1 (Txd1), or
peroxiredoxin 1 (Prdx1). Those genes encode molecules involved in
further reduction of superoxide-derived compounds (H2O2). IL-
1Ra treatment down-regulated the expression of genes encoding c-
glutamylcysteine ligase catalytic subunit (Gclc, 242%) and
glutathione reductase (Gsr, 231%), both of which contribute to
maintain the content of GSH, an antioxidant thiol, whose
mechanisms include: 1) an antioxidant potential mediated by the
peroxidase-coupled reaction; 2) regulation of cellular sulfhydryl
status and redox equilibrium; 3) regulation of expression/activation
of redox-sensitive transcription factors induced by stress-evoked
responses [45]. IL-1Ra treatment also significantly lowered the gene
encoding HO-1 (Hmox1, 249%), an antioxidant induced by supra-
physiological glucose concentrations [46], inflammation [47],
cytokines [48,49], and oxidative low density lipoproteins (LDL)
[50]. Finally, IL-1Ra treatment down-regulated the expression of
NF-E2-related factor (Nrf2, 247%), which drives the expression of
several genes, such as Gclc and Hmox1 [51].
As shown in Fig.1C, IL-1Ra reduced mRNA islet levels of
TLR4 (255%), MyD88 (222%) and NF-kB( 248%), in addition
to mRNA down-regulation of various cytokines/chemokines
(including IL-1b), as shown elsewhere [52]. Not surprisingly
therefore, IL-1Ra treatment also down-regulated the expression of
genes encoded by macrophages or immature myeloid cells, which
infiltrate GK islets at this age [6]. For example, the mRNA levels
of MHC (major histocompatibility complex) class II (H2-Ea),
CD53, and CD74 (macrophage inhibitory receptor or MIF) were
strongly reduced: 270%, 240%, and 278%, respectively).
Moreover, the genes encoding the main three extracellular matrix
proteins constituting GK islet fibrosis (collagen I, collagen III and
fibronectin, whose genes were over-expressed in GK vs Wistar
islets [6]) were down-regulated after IL-1Ra treatment (Col1a1,
248%, Col3a1, 245%; Fn1, 249%, respectively) (Fig. 1D).
Finally, we performed immunohistochemistry for von Will-
ebrand factor (VWF), an EC marker, and for fibronectin, a main
component of GK islet fibrosis, also produced by EC [6]. Von
Willebrand factor and fibronectin islet labeling examples are
shown in figure 2 (panels A and B). As previously described [6],
islets of adult GK rats are extremely heterogeneous, compared to
age-matched Wistar islets: they showed different degrees of
endothelial alteration and fibrosis. More precisely, GK islet
vascularization appears more or less hypertrophied or even greatly
disorganized. One month of IL-1Ra treatment significantly
reduced labeling of GK islet alterations, as shown for both VWF
and fibronectin (253% and 269%, respectively).
Discussion
The origin of the recently recognized islet inflammation in T2D
is still an open question. A few studies in various spontaneous T2D
animal models (Zucker diabetic fatty, Otsuka Long-Evans
IL-1Ra & GK Islet Endothelium
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vessel alterations (leakage, hemorrhage), anomalies of blood flow,
microangiopathy [10,11,53,54] or even amyloid deposits along
vessels in type 2 diabetic patients [5]. We hypothesized that islet
inflammation might have originated from EC activation (for
review, see [7]). Using a molecular approach, we demonstrate
here, for the first time, that 10-week-old diabetic GK rats show
increased markers of endothelial microvessel activation associated
with inflammation in islets. Moreover, in vivo IL-Ra treatment
reduced most of these molecular and vascular alterations, islet
fibrosis and glycemia.
Endothelial dysfunction has already been described in old GK
rat macrovessels (mesenteric artery, thoracic aorta and cerebral
arteries) [55–59]. These studies showed adhesion molecule gene
overexpression, pronounced renal perivascular monocyte/macro-
phage infiltration, increased vascular OS, and RAS and ET-1
Table 2. Expression of genes encoding factors involved in endothelium activation and inflammation in GK islets.
Protein names Acronyms mRNA levels
Wistar (W) GK Fold of W
Dysfibrinolysis
Plasminogen activator inhibitor-1 PAI-1 0.460.1 31.563.2 q x70
*
Cellular adhesion molecules
E-selectin (CD62) E-SELE 0.860.1 11.862.3 q x14
*
Intercellular adhesion molecule-1 (CD54) ICAM-1 0.860.2 5.060.7 q x6
*
Platelet endothelial cell adhesion molecule-1 (CD31) PECAM-1 2.560.5 4.060.3 q x2
*
Vascular cell adhesion molecule-1 (CD106) VCAM-1 0.160.0 9.361.1 q x62
*
Vascular tone/oxidative stress/angiogenesis
Angiotensin-converting enzyme-1 ACE-1 3.460.9 7.360.4 q x2
*
Angiotensin receptor-1a AGTR-1a 1.460.2 2.960.3 q x2
*
Angiotensinogen AGT 3.560.7 1.660.2 Q x0.5
*
Cyclo-oxygenase-2 COX-2 0.960.2 17.364.1 q x19
*
Endothelial nitric oxide synthase eNOS 0.960.1 2.460.1 q x3
*
Endothelin-1 ET-1 0.560.2 1.460.1 q x3
*
Epoxide hydrolase 2, soluble sEH 160.0 0.160.0 Q x0.1
*
Heme-oxygenase-1 HO-1 1.860.2 45.560.1 q x25
*
Hypoxia-induced factor-1a HIF-1a 2.660.1 4.560.6 q x2
*
12-Lipoxygenase 12-LOX 0.360.1 0.360.1 R x1
NADPH-oxidase-2 NOX-2 0.960.1 2.860.1 q x3
*
Prostacyclin synthase PGIS 1.760.2 8.860.7 q x5
*
Vascular endothelial growth factor A VEGFA 2.160.2 2.360.1 R x1
Cytokines/growth factors
Caspase-1 or IL-1-converting enzyme Caspase-1 1.060.0 2.360.0 q x2
*
Interleukin-1b IL-1b 0.360.1 4.560.9 q x15
*
Interleukin-1 receptor antagonist IL-1Ra 0.160.0 3.760.2 q x34
*
Interleukin-6 IL-6 1.360.4 48.968.1 q x38
*
Transforming growth factor-b TGF-b 1.160.1 7.260.5 q x7
*
Tumor necrosis factor-a TNF-a 0.560.3 16.464.1 q x33
*
Chemokines
Chemokine GRO/KC (rodent analog of IL-8) KC or CXCL1 0.660.2 73.1615.5 q x113
*
Monocyte chemoattractant protein-1 MCP-1 or CCL2 0.360.0 66.3611.9 q x204
*
Macrophage inflammatory protein-1a MIP-1a or CCL3 1.060.3 44.765.6 q x46
*
Toll-like receptor/intracellular pathways
Inductible nitric oxide synthase iNOS 3.260.5 21.961.9 q x7
*
Myeloid differentiation primary response protein MyD88 MyD88 0.860.2 1.760.1 q x2
*
Nuclear factor kappa B (p65) NF-kB1 . 0 60.1 2.460.1 q x2
*
Toll-like receptor-2 TLR-2 1.060.1 4.461.1 q x4
*
Toll-like receptor-4 TLR-4 0.460.1 1.960.2 q x4.8
*
Total RNA was extracted from freshly isolated islets of 2.5-month-old male Wistar and GK rats and quantitative RT-PCR was performed for the indicated genes and
normalized to a housekeeping gene (rpL19 or Ef1a). Data are means6SEM of 5–6 different islet isolations per group except for caspase-1 and epoxide hydrolase-2
(n=3).
*p,0.05 using Student’s t-test.
doi:10.1371/journal.pone.0006963.t002
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matory phenotype associated with the pathogenesis of atherogen-
esis [60]. Alpha-lipoic acid, AGTR-1 and ET-1 antagonists have
been shown to provide vasoprotective effects in these macrovessels
[55,57–59]. Here, we extend the observation to alterations of the
islet microvascular bed in an early stage of the GK disease
development.
As expected, 8–10-week-old diabetic GK rats showed mild
hyperglycemia, hyperinsulemia and hyperlipidemia. However, it
should be mentioned that, at this age (around onset of insulin
resistance), hyperinsulinemia may be observed or not from one
batch of GK rats to another. Our data confirm that male diabetic
GK rats exhibit increased levels of triglycerides, FFA, cholesterol
and HDL [61,62]. Notably, extensive physiological screening in
both sexes of congenics revealed the existence of GK variants at
the locus Nidd/gk5, independently responsible for significantly
enhanced insulin secretion and altered cholesterol metabolism
[61]. GK rats had marked hyperleptinemia, classically associated
with obesity and/or hyperinsulinemia [63]. Concomitantly,
peripheral OS, as reflected by oxidized RBC glutathione redox
state, was present in GK rats. Patients with high circulating
homocysteine levels, an independent risk factor of atherosclerosis
development, have an impaired ability to induce cholesterol efflux
from macrophages [33,34,64]. Homocysteine, unexpectedly lower
in diabetic rats than in controls, might be responsible for the
higher systemic GK cholesterol levels. PON-1 is an antioxidant
Figure 1. IL-1Ra treatment reduces the expression of most of the selected genes for endothelial activation, oxidative stress,
myeloid cells, and fibrosis in GK islets. Pancreatic islets were isolated from GK rats following 1-month-treatment with IL-1Ra by s.c. injections (GK
saline n=6, GK IL-1Ra (100 mg/kg/day), n=5). For each animal, total RNA was extracted from isolated islets and quantitative RT-PCR was performed
for the indicated genes, and expressed relative to GK saline.
*p,0.05 using Student’s t-test.
doi:10.1371/journal.pone.0006963.g001
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PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e6963Figure 2. IL-1Ra treatment improves vascularization and reduces fibrosis in GK islets. Immunohistochemistry was performed for von
Willebrand factor (VWF) (A) and fibronectin (B) in pancreas of young adult untreated Wistar and GK rats, and of s.c. saline- or IL-1Ra-treated-GK rats.
The border of each islet is defined by the dashed line. As shown in panel A, VWF-labeled islets from untreated GK rats are extremely heterogeneous in
terms of vascularization and extent of fibrosis, when compared to Wistar controls. In saline- and IL-1Ra-treated GK rats, immunolabeled islet area for
VWF or fibronectin was quantified for each islet and expressed as to the corresponding islet surface (n=3 GK rats for both treatment groups, n=25–
40 islets). Islets analyzed for quantification showed unchanged islet area between treatment groups.
*p,0.05 using Student’s t-test.
doi:10.1371/journal.pone.0006963.g002
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prevents LDL and HDL oxidation [65,66]. Homocysteine has
been demonstrated to be negatively correlated to the plasma
activity of PON-1 in a mouse model of homocysteine disorder
[35]. This is also the case in diabetic GK rats, which had higher
plasma PON-1 arylesterase activity than Wistar. In this regard, it
should be noted that increasing PON-1 in mice attenuated
diabetes-induced macrophage OS, diabetes development and
decreased mortality [67]. Therefore, high circulating PON-1
activity together with enhanced a-tocopherol (vitamin E) in 10-
week-old diabetic GK rats, might suggest that these rats had
already installed a systemic antioxidant defense in the lipophilic
plasma compartment. The latter might be characterized by some
degree of leptin resistance, because of the decreasing effect of
leptin on plasma PON-1 activity in Wistar rats [68], and
hyperleptinemia in GK rats. This might explain why, despite
high circulating levels of the pro-inflammatory/pro-oxidant leptin,
systemic cytokine/chemokine levels were similar in GK rats and
Wistar controls, while the levels of some of them was high in GK
rats before weaning (see below).
Molecular signs of GK islet endothelial activation and OS might
not only derive from mild chronic hyperglycemia, but also from
associated metabolic disorders, such as increased circulating FFA
and cholesterol levels and/or insulin resistance, which can precede
hyperglycemia [1–3,12–14]. Hyperglycemia alone is recognized
for a long time to be deleterious for EC [1,2,17], while it induces
pro-inflammatory cytokine/chemokine expression in monocytes
and increases their adhesion to EC [69], where hyperglycemia-
induced ROS toxicity is dependent on paracrine factor release,
like cytokines [70]. High levels of FFA signaling through TLR
receptors, cholesterol, leptin and A-II are also able to stimulate
cytokine/chemokine release from EC and/or vascular smooth
muscle cells, consequently increasing vascular OS [63,71,72]
(Fig. 3). Then, inflammatory cells migrate and produce cytokines/
chemokines and ROS [73], which might alter b-cells. Also, b-cells
are able to produce IL-1 and IL-Ra in the presence of glucose,
FFA and/or leptin [74]. A vicious cycle is therefore initiated that
will alter islet blood flow and b-cell function [7], unless the islets
are able to mount defense mechanisms.
Notably, islet capillary alterations and hemorrhage and signs of
microangiopathy are already present in normoglycemic Torii and
Zucker fatty rats, before onset of diabetes [11,53]. In Torii rats,
hyperlipidemia precedes hyperglycemia [75]. Similarly, we
observed in prediabetic 7-day-old GK vs Wistar neonates,
Figure 3. Proposed model illustrating the islet endothelial dysfunction and oxidative stress surrounding b cells in GK rats. Elevated
glucose, FFA and possibly cytokines induce endothelial activation at the islet level by eliciting reactive oxygen species (ROS) production and cytokine/
chemokine release by endothelial cells and vascular smooth muscle cells. Once released, chemokines (CXCL1, CCL2, CCL3) attract/retain immune cells
(monocytes, neutrophils), which further induce ROS and cytokine production around b cells. In addition, cytokines as well as metabolic factors (high
glucose and FFA) may act directly on b cells to increase intracellular cytokines and ROS production with consecutive antioxidant defense response.
AntagonizingIL-1byIL-1Ramayinhibitendothelialactivation/dysfunctionandsubsequentimmunecellsattraction/activation. IL-1Ramayalso bluntIL-1
signaling in b cells and subsequent ROS production and antioxidant defense response. CXCL1 (GRO1/KC, rodent equivalent of IL-8), CCL2 (MCP-1); CCL3
(MIP-1a); FFA (free fatty acids); IL-1b, interleukin-1b; IL-1Ra, interleukin-1 receptor antagonist; IL-6, interleukin-6; TNF-a, tumor necrosis factor-a.
doi:10.1371/journal.pone.0006963.g003
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together with elevated levels of chemokines (CXCL-1, CCL2 and
CCL3) [76]. Because we also found higher circulating total
cholesterol/HDL cholesterol ratio in E21.5 GK fetuses, our
present hypothesis is that dyslipidemia, together with fetal GK
hyperglycemia [77], initiates an islet microangiopathy/atheroscle-
rosis process via in utero programming [78]. Such developmental
metabolically-induced alterations may explain the high islet ROS
levels associated with altered glutathione and thioredoxin-related
gene expression recently observed in prediabetic 7-day-old GK
neonates [44]. Thus, using oligo GEArrays targeted at endothe-
lium and cardiovascular disease biomarkers, we showed a
significant upregulation of genes encoding various inflammatory
molecules [76], while the expression of genes encoding eNOS, E-
selectin, VCAM-1, IL-1b, IL-1Ra, IL-6, TNF-a, TLR-4 and
MyD88 (upregulated in 10-week-old GK rats) was similar in 1-
week-old prediabetic GK and Wistar islets (data not shown).
After diabetes onset, however, we showed in GK islets that most
of the selected 32 genes, which were up-regulated, encoded
deleterious molecules involved in microangiopathy/atherosclero-
sis. Some molecules are more or less specific to endothelium (such
as PAI-1, VCAM-1, E-selectin, PECAM-1 and eNOS), while part
of endothelial activation includes inflammatory products not
specific to endothelium. For example, cytokines and chemokines
can be produced by different cell types, including EC, VSMC,
macrophages, granulocytes, even b-cells or other endocrine cells
[7]. As hypothesized, there was an over-expression of genes
encoding: anti-fibrinolytic agent, cellular adhesion molecules,
cytokines/chemokines, growth factors and caspase 1, which
cleaves pro-IL-1 and pro-IL-18 in their active forms [79]; and
finally TLRs, which are stimulated by FFA and involved in
atherosclerosis [37], and molecules involved in TLR and IL-1
signaling: MyD88, NF-kB and iNOS. The majority of molecules
selected here are known to be modulated at the transcriptional
level. However, a few of them, particularly NF-kB and HIF-1a,
are regulated at the post-transcriptional and even post-transla-
tional level. Therefore, their mRNA levels do not correlate
systematically with their transcriptional activity. Here, however,
increased gene NF-kB expression was accompanied with more
translational activity, because of its association with gene
upregulation of IL-1 and iNOS, 2 molecules known to be under
NF-kB regulation. In addition, mRNA levels of other genes under
NF-kB regulation (antioxidant/antiapoptotic genes) were also
elevated in 10-week-old GK islets [80].
The GK islet iNos overexpression should be underlined on the
basis of the following data: 1) studies using iNOS-deficient mice
showed that iNOS plays an important role in the pathogenesis of
vascular lesions characteristic of the early stages of diabetic
retinopathy, preventing leukostasis [81]; 2) granulocytes infiltrate
diabetic GK islets [6], express iNOS and produce ROS [73]; 3)
granulocytes induce cardiomyocyte injury after myocardial
ischemia/reperfusion by an iNOS-derived OS and peroxynitrite-
mediated mechanism [82]; 4) in the aortic tissue of diabetic GK
rats, superoxide production is increased but NO bioavailability
decreased [56]. This is associated with elevated eNOS protein
expression and low levels of its cofactor tetrahydrobiopterin,
increased nitrosylated protein content and expression of the
superoxide-generating enzyme NADPH oxidase (particularly,
NOX-2). These data suggest that diabetes triggers ROS
production from the NADPH oxidase, leading to tetrahydrobiop-
terin oxidation, eNOS uncoupling, and oxidative NO inactivation
with subsequent peroxinitrite formation [83]. Moreover, increased
expression of NOX-2 and eNOS mRNA and protein levels have
been observed in the mesenteric arteries of streptozotocin-induced
diabetic apolipoprotein-E-deficient mouse [84]. Similarly, genes
encoding NOX-2 and eNOS were also up-regulated in our
diabetic GK islets, together with elevated eNOS protein level
(unpublished data) and increased GK islet NO production [85],
therefore strenghtening eNOS uncoupling. Finally, it should be
noted that: 1) eNOS expression is stimulated by hypercholester-
olemia, TNF-a, TGF-b and hypoxia; 2) NADPH oxidase
expression is stimulated by glucose, FFA and cytokines in rat
pancreatic islets and a clonal b-cell line [86]; and 3) high glucose
levels downregulate the number of monocytic calveolae, which
mediate the intracellular lipid transport, through NADPH
oxidase-induced OS [87]. The gene encoding the pro-inflamma-
tory/pro-oxidant COX-2 enzyme was strongly up-regulated in
GK islets. Notably, inhibition of COX-2 gene or its deletion in
macrophages protects against atherosclerosis [88]. Regarding b-
cell function, COX-2 over-expression could be deleterious,
because its selective inhibition is able to enhance glucose-induced
insulin secretion through a reduction of prostaglandin E2 [89].
Among other genes that were found to be up-regulated in
diabetic GK islets are those encoding several vasoconstrictor
agents, such as ET-1 and RAS-linked molecules. Endothelins
activate NADPH oxidases, thereby increasing superoxide produc-
tion and OS, and consequently leading to endothelial dysfunction
[90,91]. ET-1 has also been shown to stimulate in vitro the release
of IL-1b, TNF-a and IL-6 from monocytes [92] and has marked
vasoconstrictor effect on mouse pancreatic islet vasculature, either
in vivo or in vascularly perfused islets [93]. As already mentioned,
circulating ET-1 levels are elevated in aged GK rats and ET-1
antagonists ameliorate their macrovessel alterations [58]. The
presence of various RAS components has been described at the
islet level [94], and A-II-mediated signal through AGTR-1
involves NADPH activation, superoxide production and eNOS
uncoupling [72]. In the diabetic retina, A-II induces leukostasis via
NADPH activation [95]. AGT, ACE, and or AGTR-1 mRNA
and protein levels are elevated in arterial cells of type 2 diabetic
patients, and RAS inhibition reduces the onset of T2D and
prevented atherosclerosis [96]. Hypercholesterolemia stimulates
angiotensin peptide synthesis and contributes to atherosclerosis
through the AGTR-1 [97]. Moreover, in streptozotocin-induced
diabetic mouse aortas, the AGTR-1 blocker candesartan or the
ACE inhibitor captopril markedly attenuates eNOS-derived ROS
production, while augmenting NO bioavailability, implicating
eNOS recoupling [98]. In db/db mouse islets, candesartan,
ameliorates b-cell function, decreases OS markers and fibrosis,
and prevents EC loss [99]. As expected, GK islets showed an up-
regulation of ACE, AGTR-1 genes but an AGT gene down-
regulation, which could be linked to the local insulin inhibitory
effect on AGT mRNA expression in EC [100].
In addition to the up-regulated genes with deleterious effects,
we noted a few genes, whose modulation would be supposed to
exert protective effects. This is the case for the gene encoding
prostacyclin synthase (Ptgis), which is stimulated by IL-1b,T N F -
a and TGF-b, and produces prostacyclin (PGI2), a potent
vasodilatator agent [101]. Two other over-expressed genes, also
stimulated by cytokines and hypoxia, encode molecules with
antioxidant and/or pro-angiogenic effects: HO-1 and HIF-1a.
HO-1, whose gene expression was markedly up-regulated in GK
islets, is a potent antioxidant agent, which is able to decrease
MCP-1 but increase VEGF in EC [102], inhibit their adhesion
molecules expression [103] and protect them from glucose-
induced apoptosis [104]. HO-1 induction improves pancreas
graft survival by preventing pancreatitis after transplantation,
and protects pancreatic microcirculatory dysfunction after
ischemia/reperfusion in rats [105,106]. HIF-1a,l i k eN F - kB, is
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The HIF-1a overexpression in GK islets is possibly linked to
vessel alterations. We also show e dt h a tac r u c i a lt a r g e tg e n eo f
HIF-1a, Ldha (encoding lactate deshydrogenase A) was also
overexpressed in GK islets [80]. HIF-1a regulates several pro-
angiogenic genes, eNOS, HO-1, MIF, and VEGF [107]. Because
of concomitant gene upregulation of eNOS and HO-1, it is
highly probable that HIF-1a activity was also stimulated in GK
islets. However, VEGF gene expression showed no change. This
observation might be of importance in the context of T2D and
atherosclerosis, where defects in endothelial precursor cells were
recently recognized [108,109]. GK rats might present a deficient
angiogenesis due to lack of VEGF response and also possible
eNOS uncoupling, because VEGF-induced-eNOS is an efficient
pathway of angiogenesis [110,111] as well as COX-2 [112]. In
this context, the lack for GK rats to increase blood flow and islet
mass after 60% pancreatectomy as opposed to Wistar rats should
be noted [113].
IL-1Ra, the natural IL-1 antagonist, is another molecule of
interest in this study for several reasons. It has been shown to: 1)
play a crucial role in the prevention of inflammatory diseases; 2)
counteract deleterious effects of IL-1 members involved in insulin
resistance and diabetes; 3) reduce hyperglycemia and improve b-
cell function in type 2 diabetic patients [29,114,115]. In addition,
some haplotypes of the IL-1Ra gene have been found to be
correlated with increased cardiovascular disease risk in patients
with or without diabetes and IL-1Ra is being to be used in
atherosclerosis [31,116,117]. Compared to Wistar, untreated GK
islets showed a marked IL-1Ra gene up-regulation, which was
unable to counteract spontaneously in situ the consequences of the
concomitant strong IL-1b gene up-regulation. In this regard, on
can note that: 1) a very high IL-1Ra/IL-1 ratio is necessary to
counteract IL-1 effects; 2) in situ a very low IL-1b concentration
can exert its pleiotropic action and part of the latter may become
IL-1-independent with time; 3) and/or the GK islet inflammatory
process could be triggered concomitantly by other factors, such as
TLR activation via dyslipidemia [71]. By contrast, 100 mg/kg/
day IL-1Ra treatment of GK rats was able to significantly down-
regulate most selected genes for endothelial activation, all
cytokines/chemokines and their pathways, myeloid cell infiltra-
tion, and ECM proteins. Concomitantly, most antioxidant gene
expression was down-regulated, particularly those known to be
activated by IL-1 at the EC level [118] and serum level of the
antioxidant PON-1 was back to age-matched (8-week-old) Wistar
values after IL-1Ra in vivo (data not shown). As expected, IL-1Ra
treatment reduced islet hyper-vascularisation and islet fibrosis in
GK rats. These data highlight the primary role of IL-1 in the
pathogenesis of islet microangiopathy in a spontaneous T2D
model (Fig. 3). In this regard, co-expression of IL-1Ra and VEGF
improves human islet survival, which is strictly dependent upon
adequate revascularization [119].
Concerning IL-1Ra-induced islet endocrine modifications, we
recently described elsewhere [52]: 1) no change of the percentage
of pancreatic b-cell area between sham (saline) and IL-1ra-treated
GK rats, which would be in agreement with data published on the
high fat diet (HFD) fed mouse [30]; 2) IL-1Ra enhancement of the
expression of insulin processing enzymes, proconvertase 1 and 2,
concomitant with increased insulin gene expression (INS1 and
INS2): indeed, IL-1b downregulates both proconvertase expres-
sion, impairing insulin processing, either alone or in combination
with other cytokines such as IL-6 and TNF-a [120–123]. In GK
rats, IL-1Ra reduces islet IL-1b, IL-6, and TNF-a mRNAs and IL-
6 production, likely improving insulin processing, as reflected by
their better circulating pro-insulin/insulin ratio.
The beneficial effects of IL-1Ra concerning GK glucose
homeostasis appears to be somehow limited based on the glycemia
values measured at the end of treatment, as shown here. However:
1) the effect of IL-1Ra on glycemia varied greatly from one day to
another, despite our attempt to control as best as possible
environmental conditions, but the highest dose of IL-1Ra
(100 mg/kg/day) administered during 1 month decreased the
AUC by 50% [52]; 2) glycemia is the result of insulin production
and action and involvement of counterregulatory hormones,
notably from from a-cells. In this regard, because increased IL-6
release by GK islets may have increase their a-cell mass, as
described in response to HFD in mice [124], IL-1Ra, which
reduced GK islet IL-6 release, might have consequently diminish
their a-cell mass. However, adult Wistar and GK rats have similar
a-cell mass and glucagonemia [125] and 100 mg/kg/day IL-1Ra
in vivo did not modify GK glucagonemia (data not shown); 3) IL-
1Ra appears less effective on insulin resistance at higher dose [52];
4) the time of treatment onset, the dose and the duration of
treatment could be improved; 5) TLR activation by FFA may be
concomitantly at work in GK rats and IL-1Ra treatment did not
modify circulating GK lipid parameters [52].
Last but not least, the drastic under-expression of the soluble
epoxide hydrolase (sEH) might represent the major attempt to
compensate the defects triggered by metabolically-induced
inflammation in GK islets. Indeed, sEH is implicated in the
metabolism of epoxyeicosatrienoic acids (EETs) (see for reviews,
[126–128]). These EETs are derived from arachidonic acid by
cytochrome P450 epoxygenases. Their degradation by sEH
generate dihydroxyeicosatrienoic acids, which are less active than
their parent epoxides. Decreased sEH activity would therefore be
expected to increase intracellular EET levels and prolong their
beneficial effects, which include: 1) potent vasodilatation; 2)
marked anti-inflammatory action [129]; 3) antioxidant effect by
inducing the expression of a set of antioxidant genes, including
thioredoxin and superoxide dismutase, as described in GK rat
islets [44]; 4) beneficial effects on vessels: EETs inhibit the
migration and proliferation of VSMC and, by contrast, stimulate
EC proliferation and angiogenesis, particularly in response to
hypoxia [127]. Very recent data showed that sEH inhibitors
attenuate the progression of renal damage in diabetic GK rats
from Taconic and also the development of atherosclerosis in
apolipoprotein-E-knockout mice [130,131]. Moreover, it has been
described several polymorphisms in the gene encoding human
sEH that encode variants with altered catalytic activity. Some of
these variants are associated with increased risk of atherosclerosis
(for review, see [127]).
In conclusion, these data offer a better understanding of the
pathophysiology of islet behaviour in a spontaneous T2D animal
model, where both pro- and anti-vasoconstrictor, pro- and
antioxidant, pro- and anti-inflammatory, and pro- and anti-
angiogenic mechanisms are concomitantly at play in islets during
disease progression. The protective mechanisms may thus explain
long-lasting mild hyperglycemia in GK rats, despite early islet
endothelial activation associated with inflammation and OS.
These data also highlight the crucial role of IL-1 in triggering islet
OS. Therefore, counteracting endothelial cell inflammation as
early as possible is one way to prevent OS-related disorders in type
2 diabetes pathophysiology.
Methods
Animals
All animal experiments were conducted on fed age-matched
male GK and nondiabetic Wistar rats from our local colonies
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Gene Sequences
Ace1 Forward: GCGGAGTCGATGCTGGAGAA
Ace1 Reverse: GTGGCCCATCTCGTGGTGTA
Agt Forward: CTCCCAGAGCCAACCTTTGA
Agt Reverse: CAGCATCTTGTACATGCGGAAA
Agtr1a Forward: CTGGCAGAAATGCAATCTCATCA
Agtr1a Reverse: GCCCTTTGGGAGTTGAACAGAA
Alox15 Forward: GGGCCACTGCTGTTCGTAAGA
Alox15 Reverse: GCCCTGAACCCATCGGTAA
Casp 1 Forward: CCTGTGCGATCATGTCACTAA AA
Casp 1 Reverse: GCCAGGTAGCAGTCTTCATTACAA
Cat Forward: GGGTGGTGCTCCCAACTACTA
Cat Reverse: CACCTGAGTGACGTTGTCTTCA
Cd53 Forward: GCGTGGTTTCACTCCAATTTC
Cd53 Reverse: GGACATCCCCAGCACCTGTA
Cd74 Forward: CCAGGACCACGTGATGCA
Cd74 Reverse: CCCCTTCAGCTGTGGGTAGTT
Col1a1 Forward: CCCAACCCCCAAAAA
Col1a1 Reverse: CTGCGTCTGGTGATACATATTCTTCT
Col3a1 Forward: AGCTGGCCTTCCTCAGACTTC
Col3a1 Reverse: GCTGTTTTTGCAGTGGTATGTAAT
Cox2 Forward: CGCTTCTCCCTGAAACCTTACA
Cox2 Reverse: GGAGAATGGAGCTCCAAGTTCTA
Edn1 Forward: GCCAGTGTGCTCACCAAAAAGA
Edn1 Reverse: GGACAGGGTTTTCCCTTCTTGAA
eNos Forward: CACCCGGACAACCTCATCA
eNos Reverse: CTGCTCATTTTCCAAGTGCTTCA
Ephx2 Forward: ACCCATCGGTGACCTCCAA
Ephx2 Reverse: AAGGCCACGTCAGAAATGAAA
Fn1 Forward: CCTACGGATGACTCATGCTTT
Fn1 Reverse: CAGATAACCGCTCCCATTCC
Gclc Forward: GCCGTGGTGGATGGGTGTA
Gclc Reverse: CCACGTCGACTTCCATGTTTTCA
Gpx1 Forward: GTGCGAGGTGAATGGTGAGAA
Gpx1 Reverse: CTGGACCTACCAGGAACTTCTCAAA
GRO1/KC Forward: GGAAGAAGGGCGGAGAGATGA
GRO1/KC Reverse: CCTCTCACACATTCCTCACCCTAA
Gsr Forward: GCCCACAGCGGAAGTCAA
Gsr Reverse: GGGCAAGTCTTCCAGCTGAAA
H2-Ea Forward: CCCTCC AGCGGTCAATGT
H2-Ea Reverse: TGACACGCCTTTGGTGACA
Hmox1 Forward: GAGACGCCCCGAGGAAA
Hmox1 Reverse: GGGCCAACACTGCATTTACA
Hif1a Forward: GGCGACATGGTTTACATTTCTGATAT
Hif1a Reverse: GCTCCGCTGTGTGTTTAGTTCTTT
iNos Forward: CGCTACACTTCCAACGCAACA
iNos Reverse: CGGATTCTGGAGGGATTTCA
Icam1/CD54 Forward: CGGGAGATGAATGGTACCTACAA
Icam1/CD54 Reverse: CCGCAATGATCAGTACCAACA
Il1ra Forward: GAGGAACAATTTTTGCAGGGTGTA
Gene Sequences
Il1ra Reverse: CCCAGAGGGCAGAGGCAATA
Il1b Forward: CTGGTACATCAGCACCTCTCAA
Il1b Reverse: GAGACTGCCCATTCTCGACAA
Il6 Forward: GCCACTGCCTTCCCTACTTCA
Il6 Reverse: GACAGTGCATCATCGCTGTTCA
Mip1a/Ccl3 Forward: CCAAGTCTTCTCAGCGCCATA
Mip1a/Ccl3 Reverse: GCAGATCTGCCGGTTTCTCTTA
Mcp1/Ccl2 Forward: CTGGACCAGAACCAAGTGAGATCA
Mcp1/Ccl2 Reverse: GTGCTTGAGGTGGTTGTGGAAA
Myd88 Forward: CGGAGGAGATGGGTTTCGAGTA
Myd88 Reverse: CGATGCGGTCCTTCAGTTCATA
Nox2 Forward: CTGGACATCCTGGTGGTTTTCA
Nox2 Reverse: GGACCGCATCATGGTGAAGAA
NfkB/Rela Forward: CTGGCCATGGACGATCTGTTT
NfkB/Rela Reverse: CCCTCGCACTTGTAACGGAAA
Nrf2 Forward CCACGTTGAGAGCTCAGTCTTCA
Nrf2 Reverse GACACTGTAACTCGGGAATGGAAA
Pai1/Serpine1 Forward: CCGACCAAGAGCAGCTCTCTGTA
Pai1/Serpine1 Reverse: GTGCCGAACCACAAAGAGAAA
Pecam1/Cd31 Forward: GGCCCTGTCACGTTTCAGTTTTA
Pecam1/Cd31 Reverse: CCTGCTCCTTGCTAGTTTGTTCA
Prdx1 Forward: GCATGGATTAACACACCCAAGA
Prdx1 Reverse: GCCCCTGAAAGAGATACCTTCA
Ptgis Forward: CGCTGGCTACCTGACCCTGTA
Ptgis Reverse: GCCAGTTTGGGGAGCATCA
Sele/Cd62 Forward: GCCAGCCCTCTACCAGAATGA
Sele/Cd62 Reverse: CCCAAATTCCAGAGTGACGAAGA
Sod1 Forward: GCCGTGTGCGTGCTGAA
Sod1 Reverse: GCCTTGTGTATTGTCCCCATA
Sod2 Forward: GGCCAAGGGAGATGTTACAA
Sod2 Reverse: GACCCAAAGTCACGCTTGA
Tgfb1 Forward: GAGCCCGAGGCGGACTACTA
Tgfb1 Reverse: CCCGAATGTCTGACGTATTGAAGA
Tlr2 Forward: Rn02133647_s1 These were purchased
from AB, this is the assay number, the
rest is proprietary.
Tlr2 Reverse: Rn02133647_s1
Tlr4 Forward: CGCTTTCAGCTTTGCCTTCA
Tlr4 Reverse: GCCAGAGCGGCTACTCAGAAA
Tnfa Forward: GGGGCCTCCAGAACTCCA
Tnfa Reverse: GGAGCCCATTTGGGAACTTCT
Txd1 Forward: GGATGTTGCTGCAGACTGTGAA
Txd1 Reverse: GGCTTCGAGCTTTTCCTTGTTA
Vcam1/CD106 Forward: GCTCTTGTTTGCCTCGCTAA
Vcam1/CD106 Reverse: GTGGGTTCTTTCGGAGCAA
Vegfa Forward: CCAGGAGTACCCCGATGAGATAGA
Vegfa Reverse: GGTGAGGTTTGATCCGCATGA
doi:10.1371/journal.pone.0006963.t003
Table 3. Cont.
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care, established by the French National Center for Scientific
Research. Characteristics of the nonobese GK rat model of T2D
maintained in our colony at the University Paris-Diderot together
with the Wistar control rats have been previously described [32].
Two and a half-month-old male rats were killed by decapitation
and blood and pancreata collected for measurement of metabolic
parameters, islet isolation and quantitative RT-PCR analysis or
pancreas immunohistochemistry.
Metabolic parameters
Basal morning glycemia was determined with a glucometer.
Serum insulin was assayed by ELISA (Mercodia). FFA levels were
quantified using an enzymatic colorimetric assay (NEFA C) (Wako
Chemicals GmbH). Cholesterol, HDL, and triglyceride serum
levels were determined by using colorimetric assays (Penta
Cholesterol CP kit, HDL cholesterol direct kit and Pentra
Triglycerid CP kit, respectively, ABX Diagnostics). To measure
glutathione, 50 ml of RBC were added to 450 ml of a mixture (1:5
v/v) of EDTA (1%)/metaphosphoric acid (5%), and 100 or 200
islets were mixed with 5% metaphosphoric acid (300 ml). After
centrifugation (3000 g, 10 min, 4uC), reduced glutathione (GSH)
and its oxidized form (GSSG) were identified in supernatants by
reverse-phase HPLC with electrochemical detection [132]). Total
glutathione content, referred to as ‘‘equivalent GSH’’ (Eq GSH), is
the sum of GSH and doubled GSSG concentrations
(2GSHRGSSG). The glutathione redox state is: [total forms]
6100, with [total forms] = [oxidized form]+[reduced form].
Alpha-tocopherol was determined in heparinated plasma (100 ml)
extracted with 2-propanol (400 ml) [133]. Plasma homocysteine
was assayed by using the fluorimetric HPLC method previously
described [134]. PON-1 activity assay was performed on 5 mlo f
plasma. PON-1 arylesterase activity toward phenyl acetate was
quantified spectrophotometrically using 20 mM of Tris-HCl,
pH 8.3 with 1 mM of CaCl2 and 10 mM of phenyl acetate
(Sigma-Aldrich). The reaction was performed at room tempera-
ture for 1 min by measuring the appearance of phenol at 270 nm
with the use of continuously and automated recording spectro-
photometer. All values were corrected for non-enzymatic hydro-
lysis. Serum leptin, cytokines and chemokines were assayed using
Luminex
TM (Millipore, Switzerland) [124].
Islet isolation and mRNA analysis
Pancreatic islets were isolated using collagenase (Boehringer
Mannheim) and then handpicked under a stereomicroscope [135].
Total RNA was isolated from islets using the RNeasy mini kit
(Qiagen) and its concentration determined by optical density at
260 nm. To remove residual DNA contamination, the RNA
samples were treated with RNAse-free DNAse (Qiagen) and
purified with RNeasy mini-column (Qiagen). Total RNA (4 mg)
from each islet sample was reverse transcribed with 40 U of M-
MLV Reverse Transcriptase (Invitrogen) using random hexamer
primers. The primers used were derived from rat sequences and
designed using OLIGO6 (see Table 3). Quantitative RT-PCR
amplification reactions were carried out in a LightCycler 1.5
detection system (Roche) using the LightCycler FastStart DNA
Master plus SYBR Green I kit (Roche). Reverse transcribed RNA
(10 ng) was used as the template for each reaction. All reactions
were run in duplicate with no template control. The PCR
conditions were: 95uC for 10 min, followed by 40 cycles at 95uC
for 10 s, 60uC for 10 s and 72uC for 10 s. Changes in mRNA
expression were calculated using difference of CT values as
compared to a housekeeping gene (rpL19 or Ef1a), and expressed
relative to controls.
In vivo IL-1Ra treatment
IL-1Ra (kindly donated by Amgen, CA, USA) treatment of GK
rats was performed by twice daily subcutaneous injections
(100 mg/kg/day). Treatment was initiated 3 days following
weaning at 4 weeks of age, i.e., after onset of mild fed
hyperglycemia [32]. IL-1Ra treatment, which was given during
growth of the animals, had no effect on body weight. Subcuta-
neous (s.c.) injection experiments were stopped 4 weeks after
initiation of treatment and the animals sacrificed for islet isolation
followed by quantitative RT-PCR or pancreas immunohistochem-
istry.
Immunohistochemistry
GK rat pancreatic cryosections were incubated with rabbit anti-
fibronectin (1/40, Novotec) or rabbit anti-VWF (1/100, Dako),
followed by swin anti-rabbit secondary antibody (1/100, Dako) as
previously described [6]. Antibody-stained surface areas were
quantified blindly by measuring the surface area labeled by each
marker in a given islet and expressing it to the whole surface of this
islet (in 25–40 islets in 3 animals per treatment group), using an
Olympus BX40 microscope.
Statistics
Data are presented as means6SEM. Statistical analyses used an
unpaired Student’s t-test or ANOVA as appropriate. Significance
was defined as p,0.05.
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